Publications
Aggarwal R, Bhatt DL. The potential of artificial intelligence in clinical trials. European journal of clinical investigation. 2026. PMID: 41761496
Correia N, Johnson K, Durr M, Grimes BA, Lazar AA, Sarkar U, Ha PK, Chen L, Wai KC, Likhterov I, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR, Heaton CM, El-Sayed I, George J, Xu MJ. Timely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum. Laryngoscope investigative otolaryngology. 2026. PMID: 41767548
Correia N, Johnson K, Durr M, Grimes BA, Lazar AA, Sarkar U, Ha PK, Chen L, Wai KC, Likhterov I, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR, Heaton CM, El-Sayed I, George J, Xu MJ. Timely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum. Laryngoscope investigative otolaryngology. 2026. PMID: 41767548
L'Espérance K, Lin K, Lichtensztajn D, Christoph Soerensen SJ, Gulati S, Deng Z, Leppert JT, Oh DY, Sakoda LC, Washington SL, Meng MV, Chan JM, Langston ME, Cheng I, Chung BI, Graff RE. Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019. Lancet regional health. Americas. 2026. PMID: 41800233
Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH, Chen DL, Chi KN, Childs DS, Dahut W, Emmett L, Fizazi K, Gafita A, George DJ, Hermann K, Hofman MS, Hope T, Hussain M, Kelly WK, Kessler E, Kuo PH, Lang J, Liu G, Marshall CH, Morgans AK, McKay RR, Nanus D, Nelson P, Paller C, Reichert ZR, Ryan CJ, Sartor AO, Schöder H, Schwartz LH, Sharifi N, Stadler WM, Stein M, Sternberg CN, Szmulewitz RZ, Tagawa ST, Sokolova AO, Wyatt AW, Yamoah K, Yu EY, Halabi S, Scher HI, PCWG4 Writing Group. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41744290
Rugo HS. Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer. The New England journal of medicine. 2026. PMID: 41740036
Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urologic oncology. 2026. PMID: 41760529
Ma RK, Tsai PY, Farghli AR, Shumway A, Kanke M, Gordan JD, Gujral TS, Vakili K, Nukaya M, Noetzli L, Ronnekleiv-Kelly S, Broom W, Barrow J, Sethupathy P. Correction: DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. PLoS genetics. 2026. PMID: 41746900
Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T. WBC Growth Factors: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41740078
Wood WA, Kumar SK, Semmel E, James S, Schroeder MA, Chung DJ, Rosenberg AS, Zonder JA, Rubinstein SM, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson LD, Derkach A, Geyer S, Usmani SZ. Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma. Blood advances. 2026. PMID: 41734388
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS. Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. Breast (Edinburgh, Scotland). 2026. PMID: 41830752
Raizenne BL, Koshkin VS, Zhu A, Ben-David R, Dufault SM, Eraky A, Friedlander TW, Hong JC, Wong AC, Chou J, Chu C, Mar N, Ma TM, Sfakianos JP, Porten S, Seyedin SN. Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2026. PMID: 41864146
Raizenne BL, Koshkin VS, Zhu A, Ben-David R, Dufault SM, Eraky A, Friedlander TW, Hong JC, Wong AC, Chou J, Chu C, Mar N, Ma TM, Sfakianos JP, Porten S, Seyedin SN. Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2026. PMID: 41864146
Raizenne BL, Koshkin VS, Zhu A, Ben-David R, Dufault SM, Eraky A, Friedlander TW, Hong JC, Wong AC, Chou J, Chu C, Mar N, Ma TM, Sfakianos JP, Porten S, Seyedin SN. Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2026. PMID: 41864146
Kumar J, Jensen A, Lu R, Khanna V, Stehr H, Spinner M, Fernandez-Pol S, Greenberg PL, Tan B. Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype. Journal of hematopathology. 2026. PMID: 41721060
Bocobo A, Whitman J, Keenan BP, Koser KL, Kidder WA, Piawah S, Van Loon K, Behr SC, Kolli KP, Chen X, Onodera C, Pande M, Pollak M, Wang R, Babdor J, Spitzer MH, Zhang L, Fong L, Atreya CE. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer. Clinical colorectal cancer. 2026. PMID: 41826077
Bocobo A, Whitman J, Keenan BP, Koser KL, Kidder WA, Piawah S, Van Loon K, Behr SC, Kolli KP, Chen X, Onodera C, Pande M, Pollak M, Wang R, Babdor J, Spitzer MH, Zhang L, Fong L, Atreya CE. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer. Clinical colorectal cancer. 2026. PMID: 41826077
Bocobo A, Whitman J, Keenan BP, Koser KL, Kidder WA, Piawah S, Van Loon K, Behr SC, Kolli KP, Chen X, Onodera C, Pande M, Pollak M, Wang R, Babdor J, Spitzer MH, Zhang L, Fong L, Atreya CE. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer. Clinical colorectal cancer. 2026. PMID: 41826077
Bocobo A, Whitman J, Keenan BP, Koser KL, Kidder WA, Piawah S, Van Loon K, Behr SC, Kolli KP, Chen X, Onodera C, Pande M, Pollak M, Wang R, Babdor J, Spitzer MH, Zhang L, Fong L, Atreya CE. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer. Clinical colorectal cancer. 2026. PMID: 41826077
Kelley RK, Lee Y, Conway J, Kurland JF, McCoon P. T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41359405